Global Chemotherapy-Induced Nausea And Vomiting Market: Brief Overview
Chemo therapy induced nausea and vomiting significantly affects the treatment of patients who are suffering from cancer and undergoing chemotherapy. Nausea and vomiting are the side effects which are commonly associated with chemotherapy and may occur within 24 hours of chemotherapy or between 24 hours and five days after chemotherapy. With increasing and continuous rise in the number of people suffering from cancer and therefore an increasing number of people undergoing chemotherapy, it is estimated that the global CINV market will witness a healthy growth in the future. Approximately 14.1 million people across the globe have been diagnosed with cancer in 2012 as per and online cancer database GLOBALCAN. This market is anticipated to reach an evaluation of US$1.88 bn by 2020.
As CINV can be an obstruction to the progress of cancer patients undergoing chemotherapy, the demand for CINV drugs is increasing rapidly. It has become absolutely crucial for oncologists to prescribe the correct drug for treating chemotherapy-induced nausea and vomiting to alleviate the discomfort and pain among patients as well as to be able to carry out further treatment without any delay.
Global Chemotherapy-Induced Nausea And Vomiting Pipeline Drugs Market: Trends and Opportunities
At present the effect of drugs which are available in the market in order to manage chemotherapy-induced nausea and vomiting (CINV) are: Aloxi (palonosetron), Zofran generic (ondansetron), Kytril generic (granisetron), Emend (aprepitant) and Akynzeo (netupitant-palonosetron FDC). It is expected that in the years to come two new drugs will be introduced. They are: rolapitant and SUSTOL (APF-530). The approval of drugs such as rolapitant and SUSTOL is driving the growth of the global chemotherapy-induced nausea and vomiting drugs market. With several new drugs in the pipeline, it is expected that the future of the chemotherapy induced nausea and vomiting drugs market will be bright, and it will encourage doctors to prescribe new drugs. The approval of new drugs will also help the market to grow. On the other hand, the patent expiry of leading drugs such as Emend, Aloxi, and others is expected to negatively impact the revenue of the chemotherapy-induced nausea and vomiting drugs market.
Global Chemotherapy-Induced Nausea And Vomiting Market: Geographical Analysis
On the basis of geography, the global chemotherapy-induced nausea and vomiting drugs market is segmented into North America, Europe, Asia Pacific, and the Rest of the World. Of these, North America has been leading in terms of revenue within the CINV drugs market. This is on account of the approval of important drugs such as Rolapitant and SUSTOL. The launch of pipeline drugs for chemotherapy-induced nausea and vomiting in Europe is also expected to drive the market in Europe. Apart from these two regions the growing incidences of various types of cancer in the Asia Pacific as well as the Rest of the World will ensure that both of these regions will be promising markets for chemotherapy induced nausea and vomiting drugs market. Emerging economies such as China and India are striving to achieve improved and efficient healthcare infrastructure. This in turn is expected to bode well for the chemotherapy-induced nausea and vomiting drugs market in the Asia Pacific region.
Global Chemotherapy-Induced Nausea And Vomiting Drugs Market: Companies Mentioned
The global chemotherapy-induced nausea and vomiting drugs market is characterized by a number of generic manufacturers in the vendor landscape. They are: Barr Laboratories, Inc., Baxter Healthcare, Sun Pharma, Teva Pharmaceuticals Mylan Pharmaceuticals, Inc., Sandoz (Novartis AG), and Orchid Healthcare. Some of the other important companies within the global chemotherapy induced nausea and vomiting drugs market are: Heron Therapeutics, Inc., Helsinn Holding S.A., Merck & Co., Inc., GlaxoSmithKline plc, and Tesaro, Inc.